Pfizer Corporation

Other

Warner-lambert Company

Kevin James Filipski

Meihua Mike Tu

Angel Guzman-Perez

Jeffrey Allen Pfefferkorn

Mary Theresa Didiuk

Benjamin Dawson Stevens

Gary Erik Aspnes

Esther Cheng Yin Lee

Samit Kumar Bhattacharya

David Andrew Griffith

Bethany Lyn Kormos

Yuan Zhang

David James Edmonds

Matthew Richard Reese

Rachel Jane Roth Flach

Leanne Marie Buzon

Esther C Lee

Esther Cheng Lee

Kentaro Futatsugi

Christopher Franklin Bigge

Jeremy John Edmunds

Matthew Scott Dowling

Agustin Casimiro-Garcia

Aaron Smith

Dilinie Fernando

Michelle Renee Garnsey

Danette Andrea Dudley

Daniel Jonathan Smaltz

Luis Angel Martinez-Alsina

Chad Alan Van Huis

Jeffrey Thomas Kohrt

Jack Chang Hung Lee

Kimberly O'Keefe Cameron

David Christopher Ebner

Russell Alan Miller

Kimberly O'keefe Cameron

Dilinie Prasadhini Fernando

Aaron Christopher Smith

Christopher Ryan Butler

Kimberly O Cameron

Benjamin C Stevens

Brian Kenneth Raymer

Daniel Wei-Shung Kung

Daniel W Kung

Shenping Liu

Luis Angel Martinez Alsina

Kevin Francis Deboyace

Kiyoyuki Omoto

Described herein are compounds of Formula I, wherein the variables are defined herein, their use as branched-chain alpha keto acid dehydrogenase kinase inhibitors and/or degraders, pharmaceutical compositions containing such compounds and their use to treat, for example, diabetes, kidney disease, NASH and heart failure.

BCKDK inhibitors and/or degraders

Described herein are compounds of Formula I, wherein R, R, and Rare defined herein, their use as branched-chain alpha keto acid dehydrogenase kinase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, diabetes, NASH and heart failure.

BCKDK inhibitors

Described herein are compounds of Formula (I) wherein R, R, R, R, R, R, R, Rand Rare defined herein, their use as diacylglycerol acyltransferase 2 (DGAT2) inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, NASH.

Diacylglycerol acyl transferase 2 inhibitor

The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof wherein R, R, R, A, A, A, A, L, B, B, Band Bare as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.

Glucagon receptor modulators

The present invention relates to indole and indazole compounds of Formula (I) that activate 5' adenosine monophosphate-activated protein kinase (AMPK). The invention also encompasses pharmaceutical compositions containing these compounds and methods for treating or preventing diseases, conditions, or disorders ameliorated by activation of AMPK. 

Indole and indazole compounds that activate AMPK

The present invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R, R, R, A, A, A, B, B, Band Bare as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.

Quinolinyl glucagon receptor modulators

The present invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R, R, R, A, A, A, B, B, Band Bare as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon. 

The present invention relates to indole and indazole compounds of Formula (I) that activate 5' adenosine monophosphate-activated protein kinase (AMPK). The invention also encompasses pharmaceutical compositions containing these compounds and methods for treating or preventing diseases, conditions, or disorders ameliorated by activation of AMPK.

Growing community of inventors

Reading, MA, United States of America

Kevin James Filipski